Immunovant Files Definitive Proxy Statement for August Meeting
Ticker: IMVT · Form: DEF 14A · Filed: Jun 26, 2024 · CIK: 1764013
Sentiment: neutral
Topics: proxy-statement, annual-meeting, governance
Related Tickers: IMVT
TL;DR
IMVT proxy filed for Aug 12 meeting - vote on corp matters.
AI Summary
Immunovant, Inc. filed its definitive proxy statement on June 26, 2024, for its annual meeting on August 12, 2024. The company, formerly known as Health Sciences Acquisitions Corp, is seeking shareholder approval for matters related to its corporate governance and operations. The filing indicates no fee was required for this submission.
Why It Matters
This filing provides shareholders with crucial information regarding the company's upcoming annual meeting, including proposals that will be voted on, influencing corporate direction and governance.
Risk Assessment
Risk Level: low — This is a routine proxy filing for an annual meeting and does not contain new material financial or operational information that would inherently increase risk.
Key Players & Entities
- Immunovant, Inc. (company) — Registrant
- Health Sciences Acquisitions Corp (company) — Former company name
- August 12, 2024 (date) — Annual meeting date
- June 26, 2024 (date) — Filing date
FAQ
What is the purpose of this DEF 14A filing?
The purpose of this DEF 14A filing is to provide shareholders with the definitive proxy statement for Immunovant, Inc.'s annual meeting of stockholders.
When is the annual meeting of stockholders scheduled to take place?
The annual meeting of stockholders is scheduled to take place on August 12, 2024.
What was Immunovant, Inc.'s former name?
Immunovant, Inc.'s former name was Health Sciences Acquisitions Corp.
On what date was this definitive proxy statement filed?
This definitive proxy statement was filed on June 26, 2024.
Was there a filing fee associated with this document?
No, the filing indicates that no fee was required for this filing.
Filing Stats: 4,968 words · 20 min read · ~17 pages · Grade level 10.3 · Accepted 2024-06-26 06:56:24
Filing Documents
- imvt-20240331defproxy.htm (DEF 14A) — 568KB
- immunovantinc_vxprxyxgt20x.jpg (GRAPHIC) — 486KB
- immunovantinc_vxprxyxgt20xa.jpg (GRAPHIC) — 235KB
- table-capvsnl2024.jpg (GRAPHIC) — 67KB
- table-capvstsr2024.jpg (GRAPHIC) — 72KB
- 0001764013-24-000114.txt ( ) — 1753KB
SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT
SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT 18
EXECUTIVE COMPENSATION
EXECUTIVE COMPENSATION 20 EQUITY COMPENSATION PLANS AT MARCH 31, 202 4 27 DIRECTOR COMPENSATION 28 CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS 30 STOCKHOLDER PROPOSALS FOR THE 2025 ANNUAL MEETING OF STOCKHOLDERS 33 HOUSEHOLDING OF PROXY MATERIALS 34 OTHER MATTERS 34 Table of Contents IMMUNOVANT, INC. 320 West 37th Street New York, New York 10018 PROXY STATEMENT FOR THE 2024 ANNUAL MEETING OF STOCKHOLDERS To be Held on August 12, 2024 at 400 p.m. Eastern Time QUESTIONS AND ANSWERS ABOUT THESE PROXY MATERIALS AND VOTING What is the background of Immunovant On December 19, 2019, Immunovant Sciences Ltd. ("ISL") and Health Sciences Acquisitions Corporation ("HSAC") announced the closing of the transactions contemplated by the Share Exchange Agreement, dated September 29, 2019, between HSAC, ISL, the stockholders of ISL, and Roivant Sciences Ltd. ("RSL"), as representative of such sellers. Upon the closing of the transactions (the "Business Combination"), HSAC acquired 100% of the issued and outstanding common shares of ISL in exchange for shares of common stock of HSAC, and ISL became a wholly owned subsidiary of HSAC. Upon the closing of the Business Combination, we changed our name from Health Sciences Acquisitions Corporation to Immunovant, Inc. ("Immunovant" or "we"). The executive officers of HSAC resigned, and the executive officers of ISL were appointed as the executive officers of Immunovant, Inc. In addition, certain members of the HSAC board of directors resigned, and all the members of the ISL board of directors were appointed to the Board of Directors of Immunovant, Inc. (the "Board"). Why did I receive a notice regarding the availability of proxy materials on the internet Pursuant to rules adopted by the Securities and Exchange Commission (the "SEC"), we have elected to provide access to our proxy materials primarily over the internet. Accordingly, we have sent you a Notice of Internet Availability of Pr